Hospital Infection Therapeutics Market Urinary Catheters Market Size, Share, Trends, Outlook, Growth Opportunities, and Forecast 2023 - 2030

Hospital Infection Therapeutics Market is segmented By Therapeutics (Antibiotics, Antifungal therapeutics, Antiviral Therapeutics), By Application (Hospital-acquired pneumonia, Urinary tract infections, Surgical-site infections, Central line-associated bloodstream infection, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030 

Hospital Infection Therapeutics Market Report Overview

Hospital Infection Therapeutics Market report analyzes the global market size, shares, recent trends, competitive intelligence, and future market outlook. Hospital infection therapeutics technology finds application in diverse sectors such as healthcare, pharmaceuticals, and research. The market is driven by increasing demand for effective and safe therapeutics to combat hospital-acquired infections, particularly in the Asia Pacific region. Key players in the market include Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc, AstraZeneca plc, Novartis International AG, and others operating in the market.

Hospital-acquired infections, also known as healthcare-associated infections (HAI), are nosocomial caught infections that are normally not present or might be incubating at the time of admission. These infections are normally developed post-hospitalization and manifest after 48 hours of admission to the hospital.

Hospital Infection Therapeutics Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Hospital Infection Therapeutics Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. The hospital Infection Therapeutics Market in the United States and Canada produces the utmost share. Whereas the European Hospital Infection Therapeutics Market is projected to continue its presence globally from 2022 to 2029.

Hospital Infection Therapeutics Market Scope and Summary

To Get a Free Sample Click here

Hospital Infection Therapeutics Market Dynamics and Trends

Growing cases of hospital-acquired infections, increasing awareness, and increasing hospital admissions drive the growth of global hospital infection therapeutics.

The increasing awareness about healthcare-associated infections drives the global healthcare infection therapeutics market growth.

The increased awareness about hospital-acquired infections is fueling the global hospital infection therapeutics market growth during the forecast period. For instance, in May 2022, WHO launched its first-ever global report on infection prevention and control, revealing that good prevention and control programs can decrease healthcare infections by 70%. Also, seven out of every 100 patients in acute-care hospitals from high-income countries and 15 in low and middle-income countries acquire at least one healthcare-associated infection (HAI) during their hospital stay. On average, 1 of every 10 patients affected dies from their HAI. Furthermore, in 2009 the U.S. Department of Health & Human Services released the national action plan to prevent healthcare-associated infections, a roadmap to elimination (HAI National Action Plan) and made updates in 2013 and 2018 and is currently working on updating this plan with new indicator targets and data, new research and intervention efforts, and a review of the impact of the COVID-19 public health emergency on HAIs. Thus, from the data mentioned above, it is anticipated that the increasing awareness about hospital infections will drive the global hospital infection therapeutics market growth during the forecast period.

The lack of skilled and professional personnel and stringent regulations obstruct the global hospital infection therapeutics market growth.

However, the lack of skilled and professional personnel and the presence of stringent regulations will restrain the growth of the hospital infection therapeutics market in the forecast period.

COVID-19 Impact on Sepsis Diagnostic Market Growth

COVID-19 has significantly impacted the global hospital infection therapeutics market since there was a disruption in essential healthcare services. For instance, WHO pulse surveys carried out in 2020 and 2021 on the continuity of essential health services during the COVID-19 pandemic pointed out that the lack of infection prevention and control supplies and poor application of best practices were shown to be major reasons for the disruption of essential health services in 44% of countries in 2020 and 26% of countries in 2021. An estimated 50% of healthcare facilities lacked basic water supplies, 63% lacked basic sanitation services, 26% lacked hand hygiene facilities at points of care, and 60% did not have systems to safely manage healthcare waste, which led to increased cases of hospital-acquired infections. For instance, a CDC analysis published in the Infection Control and Hospital Epidemiology journal reveals continued increases in healthcare-associated infections in U.S. hospitals during 2021, the second year of the COVID-19 pandemic. Thereby positively impacting the global hospital infection therapeutics market growth.

Hospital Infection Therapeutics Market Segment and Shares

Urinary tract infections are expected to dominate the global hospital infection therapeutics market during the forecast period (2023-2030).

Urinary tract infections are estimated to dominate the global hospital infection therapeutics market during the forecast period (2022-2029). A urinary tract infection (UTI) involves any part of the urinary system, such as the urethra, bladder, ureters, and kidney. UTIs are the most typical type of healthcare-associated infection registered to the National Healthcare Safety Network (NHSN). Out of the UTIs acquired in the hospital, about 75% are related to a urinary catheter, a tube inserted into the bladder through the urethra for draining urine. Around 15-25% of all hospitalized patients require urinary catheters during their hospital stay. The prolonged use of the urinary catheter is a major risk factor for developing a catheter-associated UTI (CAUTI). In addition, according to the Asia Pacific Society of Infection Control, catheter-associated urinary tract infections (CAUTIs) are the source of approximately 20% of healthcare-associated bacteremia and the attribution for more than 50% of healthcare-associated pneumonia in nursing homes. Therefore, from the mentioned data, it is estimated that urinary tract infections will dominate the global hospital infection therapeutics market throughout the forecast period.

Hospital Infection Therapeutics Market Geographical Analysis

The North American region dominates the global hospital infection therapeutics market.

The North American region is expected to hold a large share of the global hospital infection therapeutics market in the forecast period (2023-2030). According to the Massachusetts Health & Hospital Association, HAIs account for an estimated 1.7 million infections and about 99,000 associated deaths each year, of which 32% are UTIs, 22% are Surgical Site Infections, 15% are pneumococcal infections, and 14% are bloodstream infections. Moreover, this region's increasing hospital admissions contribute to its dominance over the global hospital infection therapeutics market. For instance, the data from American Hospital Association exhibits that there are around 6,093 hospitals in 2022 functional, with a staffed bed capacity of 920,531 with total admission of around 33,356,853 with an expenditure of $ 1,213,881,001,000. In addition, the key market players such as Bristol-Myers Squibb Company, Pfizer, Inc, Actavis plc, Merck & Co., Inc., and Gilead Sciences, Inc. holding most of the global hospital therapeutics market are U.S. based ensures the dominant of this region over the global hospital infection therapeutics market. Thus, from the mentioned data, it is estimated that North America will dominate the global hospital infection therapeutics market in the forecasted period. 

Hospital Infection Therapeutics Companies and Competitive Landscape

The improved opportunities in the market for the local and global players are making the market competitive. Bristol-Myers Squibb Company, Pfizer, Inc, F. Hoffmann-La Roche Ltd, Sanofi S.A, GlaxoSmithKline plc, Basilea Pharmaceutica Ltd., AstraZeneca PLC, Actavis plc, Merck & Co., Inc. and Gilead Sciences, Inc. are some of the key market players. These key players hold the major share of the market through new approaches, new services, collaborations, acquisitions, and alliances. For instance, In July 2022, Agência Nacional de Vigilância Sanitária (Anvisa) in Brazil granted Basilea Pharmaceutica Ltd approval for marketing antibiotic Zevtera® (ceftobiprole), indicated for treating adult patients with community-acquired pneumonia (CAP) and with hospital-acquired pneumonia (HAP), except ventilator-associated pneumonia (VAP).

GlaxoSmithKline plc

Overview:        

GSK is a global biopharma company dealing with prescription and nonprescription products. GSK was founded on 27 December 2000 and had headquarters in Brentford, United Kingdom. GSK has 45+ subsidiaries which create its global presence.

Product Portfolio:

 The product portfolio of GlaxoSmithKline plc for hospital infections contains Amoxil: a penicillin antibiotic that fights bacteria employed for the treatment of diverse types of bacterial infections like tonsillitis, bronchitis, pneumonia, and infections of the ear, nose, throat, skin, or urinary tract.

Key Development:

In August 2022, GSK acquired Affinivax, Inc., a clinical-stage biopharmaceutical company.

The global hospital infection therapeutics market report would provide access to approximately 40+ market data tables, 45+ figures, and a range of 200 (approximate) pages.